NEW YORK – Scipher Medicine said today that it has completed an $82 million Series C financing led by aMoon and Northpond Ventures, with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures.
Adding the new Series C to prior fundraising, the company said it has raised $117 million in total.
Scipher plans to use the proceeds to expand commercial efforts for its PrismRA test, which employs an RNA-based molecular signature to identify individuals with rheumatoid arthritis who are unlikely to adequately respond to TNFi therapy and should consider alternative, more effective therapies.
The financing will also support research collaborations to identify novel treatment targets using the firm's growing clinico-genomic database.
"With more data being generated from tested patients every day, we are continuously serving our provider, payer, and pharma partnerships with unique insights into the most optimal treatment pathway for patients with autoimmune diseases," Scipher CEO Alif Saleh said in a statement.